Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Hormonal
Carcinoma, Ductal, Breast
Neoplasm Recurrence, Local
In this series of prospectively collected trastuzumab-refractory human breast cancers, loss of HER2 overexpression was rare, whereas activation of the PI3K-AKT pathway through loss of PTEN or PIK3CA mutation was frequently observed.